Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 18;10(7):e6087.
doi: 10.1002/ccr3.6087. eCollection 2022 Jul.

Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases

Zahra Davoudi  1 , Mohammad Hallajnejad  2 , Elena Jamali  3 , Mohammadjavad Honarvar  4
Affiliations
Case Reports

Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases

Zahra Davoudi et al. Clin Case Rep. .

Abstract

Refractory aggressive prolactinomas are detected after the unresponsiveness to conventional therapies. We report two cases that underwent temozolomide treatment and have been in near-complete remission ever since. We suggest the pathology techniques for earlier detection and, subsequently, treatment with temozolomide to reduce morbidities and better respond to therapy.

Keywords: aggressive prolactinoma; case report; pituitary neoplasms; prolactinoma; temozolomide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

FIGURE 1
FIGURE 1
(A) Coronal images of pituitary gland MRI, T1‐weighted post‐contrast demonstrate sellar mass with suprasellar and right cavernous sinus extension. (B) Post‐second surgery and radiation study shows a marked decrease in mass size with residual tumor along the cavernous sinus. (C) After TMZ treatment , there is a near‐complete response
FIGURE 2
FIGURE 2
(A) Monomorphic eosinophilic cells of prolactinoma. (B) H&E show diffuse cytoplasmic immunoreactivity for prolactin. (C) increased Ki‐67 proliferative index on IHC study
FIGURE 3
FIGURE 3
(A) Coronal image of pituitary gland MRI post‐contrast shows large mass obliterating suprasellar cistern with extension into the third ventricular floor, right middle cranial fossa, and right cavernous sinus extension. (B) Post second surgery and radiation study. (C) One‐year post‐TMZ treatment shows a significant decrease in tumor size with a small residual lesion
FIGURE 4
FIGURE 4
(A) Prolactinoma with monomorphic small cells harboring shrunken cytoplasms. (B) H&E show diffuse cytoplasmic immunoreactivity for prolactin. (C) diffuse weak nuclear staining for estrogen receptoron IHC study
See this image and copyright information in PMC

References

    1. Oh MC, Aghi MK. Dopamine agonist‐resistant prolactinomas. J Neurosurg. 2011;114(5):1369‐1379. doi:10.3171/2010.11.JNS101369 - DOI - PubMed
    1. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273‐288. doi:10.1210/jc.2010-1692 - DOI - PubMed
    1. Lin S, Zhang A, Zhang X, Wu ZB. Treatment of pituitary and other tumours with cabergoline: new mechanisms and potential broader applications. Neuroendocrinology. 2020;110(6):477‐488. doi:10.1159/000504000 - DOI - PubMed
    1. Strobel H, Baisch T, Fitzel R, et al. Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicine. 2019;7(3):69. doi:10.3390/biomedicines7030069 - DOI - PMC - PubMed
    1. Colao A, Grasso LFS, Pivonello R, Lombardi G. Therapy of aggressive pituitary tumors. Expert Opin Pharmacother. 2011;12(10):1561‐1570. doi:10.1517/14656566.2011.568478 - DOI - PubMed

Publication types

LinkOut - more resources